Free tool
FAERS Monitor: Apidra Solostar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021629 or its brand name (Apidra Solostar, Insulin Glulisine Recombinant). Reports on generic versions are filed under their own applications.
Reports
10,207
Serious
7,737
76% of reports
Hospitalization
4,127
Death reported
819
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,577
- hypoglycaemia785
- hyperglycaemia655
- drug ineffective582
- blood glucose decreased455
- dizziness407
- malaise398
- dyspnoea393
- nausea380
- vomiting348
- acute kidney injury310
- fatigue310
- asthenia305
- diarrhoea294
- diabetes mellitus inadequate control286
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 9 |
| 2006 | 73 |
| 2007 | 187 |
| 2008 | 119 |
| 2009 | 197 |
| 2010 | 291 |
| 2011 | 480 |
| 2012 | 513 |
| 2013 | 578 |
| 2014 | 867 |
| 2015 | 1,076 |
| 2016 | 615 |
| 2017 | 613 |
| 2018 | 968 |
| 2019 | 869 |
| 2020 | 576 |
| 2021 | 428 |
| 2022 | 470 |
| 2023 | 384 |
| 2024 | 345 |
| 2025 | 295 |
| 2026 | 254 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,952 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperglycaemiaSignal | 655 | 37.7 | 35.0 | 22,985 |
| hypoglycaemiaSignal | 785 | 33.9 | 31.7 | 24,670 |
| diabetes mellitus inadequate controlSignal | 286 | 33.8 | 30.1 | 8,938 |
| blood glucose decreasedSignal | 455 | 19.7 | 18.0 | 8,001 |
| blood glucose increasedSignal | 1,577 | 17.4 | 16.6 | 24,351 |
| acute kidney injurySignal | 310 | 4.2 | 3.7 | 751 |
| malaise | 398 | 1.9 | 1.7 | 164 |
| dizziness | 407 | 1.7 | 1.5 | 115 |
| asthenia | 305 | 1.7 | 1.5 | 83 |
| vomiting | 348 | 1.5 | 1.4 | 64 |
| dyspnoea | 393 | 1.4 | 1.3 | 52 |
| nausea | 380 | 1.0 | 0.9 | 0 |
| diarrhoea | 294 | 0.9 | 0.8 | 1 |
| drug ineffective | 582 | 0.9 | 0.8 | 5 |
| fatigue | 310 | 0.8 | 0.7 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.